In pediatric AML, kit mutations, particularly expressed by AML with CBF alterations, were associated with a higher cumulative incidence of relapse [88], although the relationship between kit mutations and worse outcome is controversial [89]. The gene discussed is CEBPZ; the disease is acute myeloid leukemia.